Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Mepha

Ownership
Private
Employees
~170
Therapeutic Areas
CardiovascularImmunologyOtherOncologyInfectious Diseases
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
small molecules (branded and non-branded generics)improved branded generics using new formulations or drug delivery technologies[5]

Mepha General Information

Leading Swiss generic pharmaceutical company with over one-third market share in Switzerland. Offers more than 230 branded and non-branded preparations covering a wide range of therapeutic areas. Known for high-quality standards and innovative drug delivery approaches. Active in malaria research. Now operates as part of Teva Pharmaceutical Industries.[1][2][5][6]

Contact Information

Website
https://pmc.ncbi.nlm.nih.gov/articles/PMC1803145/
Primary Industry
Biotech
Corporate Office
Basel, Basel
Switzerland

Drug Pipeline

artesunate
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Mepha's pipeline data

Book a demo

Key Partnerships

Partnerships to distribute products across Europe, Middle East, Africa, South & Central America [5]; now leverages Teva’s global partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Mepha Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Mepha's complete valuation and funding history, request access »

Mepha Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals